
|Articles|June 15, 2004
Short-term results of custom ablation stable over 2 years
Higher-order aberrations decreased in most patients, with the change from baseline reaching up to 50%.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Phase 3 NORTHSTAR trial launches for gildeuretinol in stargardt disease
2
Rising Star: Introducing Viha Vig, MBChB
3
Everest medicines acquires greater china rights to aceclidine presbyopia eye drop (VIZZ)
4
Dompé initiates phase 3 Orunea trial of cenegermin-bkbj in PCED
5





















